Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT01089127

Public ClinicalTrials.gov record NCT01089127. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease, Using Salmeterol as an Active Control

Study identification

NCT ID
NCT01089127
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
552 participants

Conditions and interventions

Interventions

  • Indacaterol Drug
  • Salmeterol 50 μg Drug
  • Placebo to indacaterol Drug
  • Placebo to salmeterol Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2010
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010
Last update posted
Aug 18, 2011

2010

United States locations

U.S. sites
69
U.S. states
28
U.S. cities
66
Facility City State ZIP Site status
Novartis Investigator Site Florence Alabama 35630
Novartis Investigator Site Jasper Alabama 35501
Novartis Investigator Site Phoenix Arizona 85006
Novartis Investigator Site Searcy Arkansas 72143
Novartis Investigator Site Fullerton California 92835
Novartis Investigative Site Rancho Mirage California 92270
Novartis Investigator Site Riverside California 92506
Novartis Investigator Site San Diego California 92120
Novartis Investigator Site Stockton California 95207
Novartis Investigator Site Temecula California 92591
Novartis Investigator Site Walnut Creek California 94598
Novartis Investigator Site Wheat Ridge Colorado 80033
Novartis Investigative Site Glastonbury Connecticut 06033
Novartis Investigative Site Stamford Connecticut 06902
Novartis Investigator Site Clearwater Florida 33765
Novartis Investigator Site DeFuniak Springs Florida 32435
Novartis Investigative Site Hollywood Florida 33021
Novartis Investigator Site Miami Florida 33145
Novartis Investigative Site Pensacola Florida 32503
Novartis Investigative Site Pensacola Florida 32504
Novartis Investigative Site Tamarac Florida 33321
Novartis Investigator Site Tampa Florida 33603
Novartis Investigator Site O'Fallon Illinois 62269
Novartis Investigator Site Florence Kentucky 41017
Novartis Investigator Site Madisonville Kentucky 42431
Novartis Investigator Site Opelousas Louisiana 70570
Novartis Investigative Site Columbia Maryland 21044
Novartis Investigator Site Edina Minnesota 55435
Novartis Investigator Site Fridley Minnesota 55432
Novartis Investigator Site Minneapolis Minnesota 55402
Novartis Investigator Site Ozark Missouri 65721
Novartis Investigator Site St Louis Missouri 63141
Novartis Investigator Site Bellevue Nebraska 68123
Novartis Investigator Site Lincoln Nebraska 68510
Novartis Investigator Site Omaha Nebraska 68134
Novartis Investigator Site Henderson Nevada 89014
Novartis Investigator Site Las Vegas Nevada 89119
Novartis Investigator Site Las Vegas Nevada 89183
Novartis Investigator Site Lebanon New Hampshire 03756
Novartis Investigative Site Cherry Hill New Jersey 08003
Novartis Investigative Site Bayside New York 11361
Novartis Investigative Site Great Neck New York 11023
Novartis Investigative Site Lake Success New York 11042
Novartis Investigative Site Larchmont New York 10538
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Shelby North Carolina 28152
Novartis Investigator Site Cadiz Ohio 43907
Novartis Investigator Site Canton Ohio 44718
Novartis Investigator Site Columbus Ohio 43215
Novartis Investigator Site Toledo Ohio 43608
Novartis Investigative Site Eugene Oregon 97404
Novartis Investigator Site Medford Oregon 97504
Novartis Investigative Site Phoenixville Pennsylvania 19460
Novartis Investigative Site Pittsburgh Pennsylvania 15243
Novartis Investigative site Charleston South Carolina 29406-7108
Novartis Investigative Site Charleston South Carolina 29407
Novartis Investigative Site Easley South Carolina 29640
Novartis Investigative Site Greenville South Carolina 29615
Novartis Investigative Site Spartanburg South Carolina 29303
Novartis Investigative Site Union South Carolina 29379
Novartis Investigator Site Cookeville Tennessee 38501
Novartis Investigator Site Dickinson Texas 77539
Novartis Investigator Site Fort Worth Texas 76104
Novartis Investigator Site McKinney Texas 75069
Novartis Investigator Site Salt Lake City Utah 84107
Novartis Investigative Site Fredericksburg Virginia 22401
Novartis Investigative site Newport News Virginia 23606
Novartis Investigative Site Richmond Virginia 23229
Novartis Investigator Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01089127, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2011 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01089127 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →